FT
TVTX icon

Fiduciary Trust’s Travere Therapeutics TVTX Stock Holding History

Fiduciary Trust’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
+6,083
New +$270K ﹤0.01% 708
2026
Q1 		– Sell
-6,083
Closed -$232K – 905
2025
Q4 		$232K Sell
6,083
-3,378
-36% -$110K ﹤0.01% 799
2025
Q3 		$226K Buy
+9,461
New +$178K ﹤0.01% 796

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiduciary Trust's TVTX Position: Q2 2026 in Review

Fiduciary Trust opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 6,083 shares worth $346K. The stake represents ﹤0.01% of the portfolio and ranks #708 among its holdings. This is a return to the name: Fiduciary Trust previously reported a position in TVTX as recently as Q4 2025.

Fiduciary Trust first reported a position in TVTX in Q3 2025 and has held it in 3 quarters since. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Fiduciary Trust held 6,083 shares of Travere Therapeutics worth $346K as of Q2 2026.
  • Travere Therapeutics was a new Fiduciary Trust position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Fiduciary Trust's portfolio in Q2 2026, its #708 holding.
  • Fiduciary Trust first reported a position in Travere Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.